Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591
This study is recruiting at 11 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Bipolar I Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 12 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Vanda Pharmaceuticals
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Vanda Investigational Site · Dothan, AL
Arkansas · 1
- Vanda Investigational Site · Little Rock, AR
Colorado · 1
- Vanda Investigational Site · Denver, CO
Georgia · 3
- Vanda Investigational Site · Atlanta, GA
- Vanda Investigational Site · Atlanta, GA
- Vanda Investigational Site · Decatur, GA
North Carolina · 1
- Vanda Investigational Site · Kinston, NC
Ohio · 3
- Vanda Investigational Site · Cincinnati, OH
- Vanda Investigational Site · Garfield Heights, OH
- Vanda Investigational Site · Westlake, OH
Washington · 1
- Vanda Investigational Site · Everett, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.